Search research articles
Contact Us
Filters
Showing results (91-100 of 107) with videos related to
Page
of 11
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
June 24, 2021
SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors
Wensheng Yu, Yongqi Deng, Brett Hopkins, et al.
Journal of Medicinal Chemistry
|
October 20, 2023
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's Disease
Solomon D Kattar, Anmol Gulati, Kaila A Margrey, et al.
Journal of Medicinal Chemistry
|
March 25, 2016
Identification and in Vivo Evaluation of Liver X Receptor β-Selective Agonists for the Potential Treatment of Alzheimer's Disease
Shawn J Stachel, Celina Zerbinatti, Michael T Rudd, et al.
Nature Communications
|
December 19, 2019
Discovery of a chemical probe for PRDM9
Abdellah Allali-Hassani, Magdalena M Szewczyk, Danton Ivanochko, et al.
Journal of Medicinal Chemistry
|
April 9, 2026
From KRAS<sup><i>G12D</i></sup> to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
Xiaoshen Ma, David L Sloman, Timothy J Henderson, et al.
Journal of Medicinal Chemistry
|
March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing
Derun Li, David L Sloman, Abdelghani Achab, et al.
ACS Medicinal Chemistry Letters
|
March 19, 2021
Carbamate and <i>N</i>-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors
Derun Li, Yongqi Deng, Abdelghani Achab, et al.
Journal of Medicinal Chemistry
|
December 30, 2021
Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors
Mitchell H Keylor, Anmol Gulati, Solomon D Kattar, et al.
Journal of Medicinal Chemistry
|
March 25, 2022
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer
Wonsuk Chang, Michael D Altman, Charles A Lesburg, et al.
Science (New York, N.Y.)
|
August 22, 2020
An orally available non-nucleotide STING agonist with antitumor activity
Bo-Sheng Pan, Samanthi A Perera, Jennifer A Piesvaux, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 107) with videos related to
Sort By:
Page
of 11
Bioorganic & Medicinal Chemistry Letters
|
June 24, 2021
SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors
Wensheng Yu, Yongqi Deng, Brett Hopkins, et al.
Journal of Medicinal Chemistry
|
October 20, 2023
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's Disease
Solomon D Kattar, Anmol Gulati, Kaila A Margrey, et al.
Journal of Medicinal Chemistry
|
March 25, 2016
Identification and in Vivo Evaluation of Liver X Receptor β-Selective Agonists for the Potential Treatment of Alzheimer's Disease
Shawn J Stachel, Celina Zerbinatti, Michael T Rudd, et al.
Nature Communications
|
December 19, 2019
Discovery of a chemical probe for PRDM9
Abdellah Allali-Hassani, Magdalena M Szewczyk, Danton Ivanochko, et al.
Journal of Medicinal Chemistry
|
April 9, 2026
From KRAS<sup><i>G12D</i></sup> to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
Xiaoshen Ma, David L Sloman, Timothy J Henderson, et al.
Journal of Medicinal Chemistry
|
March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing
Derun Li, David L Sloman, Abdelghani Achab, et al.
ACS Medicinal Chemistry Letters
|
March 19, 2021
Carbamate and <i>N</i>-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors
Derun Li, Yongqi Deng, Abdelghani Achab, et al.
Journal of Medicinal Chemistry
|
December 30, 2021
Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors
Mitchell H Keylor, Anmol Gulati, Solomon D Kattar, et al.
Journal of Medicinal Chemistry
|
March 25, 2022
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer
Wonsuk Chang, Michael D Altman, Charles A Lesburg, et al.
Science (New York, N.Y.)
|
August 22, 2020
An orally available non-nucleotide STING agonist with antitumor activity
Bo-Sheng Pan, Samanthi A Perera, Jennifer A Piesvaux, et al.
Page
of 11